FinanceDraft
GE Vernova Shares Outpace Dow Over 12 Months Despite Recent Pullback
GE Vernova gained 57.3 per cent over the past year, well ahead of the Dow’s 17.1 per cent rise, while analysts retained a reported Strong Buy consensus.
Event
Edwards Lifesciences lags the Dow despite bullish analyst outlook
GE Vernova shares rose 57.3% over the past 52 weeks, exceeding the Dow’s 17.1% gain. Analysts maintained a consensus “Strong Buy” rating, with a mean price target of US$1,257.07.
2 published stories · markets · source reliability 33%
Background
Why this event matters
GE Vernova is a Cambridge, Massachusetts-based electricity technology company operating across Power, Wind and Electrification. Its shares rose 57.3% over the reported 52 weeks, outperforming the Dow Jones Industrial Average’s 17.1% gain. Analysts retained a reported consensus “Strong Buy” rating, with a mean price target of US$1,257.07. The company was reported to have a market capitalisation of US$250.9 billion.
event-brief
Edwards Lifesciences lags the Dow despite bullish analyst outlook
GE Vernova is a Cambridge, Massachusetts-based electricity technology company operating across Power, Wind and Electrification. Its shares rose 57.3% over the reported 52 weeks, outperforming the Dow Jones Industrial Average’s 17.1% gain. Analysts retained a reported consensus “S
Reporting trail
Yahoo Finance | https://www.barchart.com/story/news/4484582/is-ge-vernova-stock-outperforming-the-dow | published 2026-09-08T10:33:04.000Z | primary sourceYahoo Finance, “Is GE Vernova Stock Outperforming the Dow?” | Primary source for performance data, company background and analyst consensus.Event digest | Concise account of the reported 12-month outperformance and price target.Retrieved context, [CLUSTER_SUMMARY] | Duplicates the event summary; useful for corroboration but not an independent source.Yahoo Finance | https://www.barchart.com/story/news/4483525/is-edwards-lifesciences-stock-underperforming-the-dow | published 2026-09-08T09:20:07.000Z | primary sourceYahoo Finance/Barchart article | Primary source for Edwards Lifesciences’ performance, earnings, guidance and analyst-consensus figures.Event digest | Concise summary of the reported stock-performance gap and analyst outlook.Retrieved context, cluster summary | Confirms the event framing and topic classification; adds no independent facts.
Fact cards
entity brief
Edwards Lifesciences lags the Dow despite bullish analyst outlook: key people and institutions
Key entities: GE Vernova Inc., Dow Jones Industrial Average, Eaton Corporation plc, Edwards Lifesciences Corporation, Boston Scientific Corporation.
faq brief
Edwards Lifesciences lags the Dow despite bullish analyst outlook: key questions
How did GE Vernova perform against the Dow? Its shares rose 57.3% over 52 weeks, compared with the Dow’s 17.1% gain. What is the reported analyst consensus? Analysts maintained a consensus “Strong Buy” rating. What was the mean price target? US$1,257.07. What does GE Vernova do?
source brief
Edwards Lifesciences lags the Dow despite bullish analyst outlook: reporting sources
Yahoo Finance | https://www.barchart.com/story/news/4484582/is-ge-vernova-stock-outperforming-the-dow | published 2026-09-08T10:33:04.000Z | primary source | Yahoo Finance, “Is GE Vernova Stock Outperforming the Dow?” | Primary source for performance data, company background and
timeline brief
Edwards Lifesciences lags the Dow despite bullish analyst outlook: timeline
Past 52 weeks: GE Vernova shares rose 57.3%, compared with a 17.1% gain for the Dow. Past three months: GE Vernova shares fell 2.2%. 2026-09-08: The cited report was published, including the analyst consensus and mean price target.
Timeline
Past 52 weeks
GE Vernova shares rose 57.3%, compared with a 17.1% gain for the Dow.
Past three months
GE Vernova shares fell 2.2%.
2026-09-08
The cited report was published, including the analyst consensus and mean price target.
FAQ
How did GE Vernova perform against the Dow?
Its shares rose 57.3% over 52 weeks, compared with the Dow’s 17.1% gain.
What is the reported analyst consensus?
Analysts maintained a consensus “Strong Buy” rating.
What was the mean price target?
US$1,257.07.
What does GE Vernova do?
It provides electricity technology across Power, Wind and Electrification.
Did GE Vernova outperform Eaton?
Yes. Eaton shares rose 18% over the reported year, compared with GE Vernova’s 57.3% gain.
How did Edwards Lifesciences perform against the Dow?
Its shares gained 11.4% over 12 months, compared with the Dow’s 17.1% rise.
What is the analyst consensus?
A “Strong Buy” rating from 30 analysts.
What is the average price target?
US$102.03, which the source says implies 13.5% upside.
What did Edwards report for the second quarter?
US$1.7 billion in sales and adjusted earnings per share of US$0.78.